# An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

> **NCT02150928** · PHASE2 · WITHDRAWN · sponsor: **Jazz Pharmaceuticals**

## Conditions studied

- Acute Lymphoblastic Leukemia (ALL)/Lymphoblastic Lymphoma (LBL)

## Interventions

- **DRUG:** Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)

## Key facts

- **NCT ID:** NCT02150928
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-05
- **Primary completion:** 2015-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02150928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02150928, "An Open-Label, Single-Arm, Multicenter Pharmacokinetic Study of Intramuscular Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02150928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*